Program
Vorinostat
Also written as “vorinostat”, “Vorinostat (SAHA)” and “MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months”.
Its studies are mostly in Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Lymphoma · Neoplasms · Rett Syndrome, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 260 open or running | phase 3since Aug 5, 2005 | Sep 10, 2004 | none ahead |
| Unravel Biosciences | 22 open or running | phase 1since Aug 14, 2025 | Aug 14, 2025 | Dec 31, 2026phase 1 · NCT07150013 |
| Jubilant DraxImage | 10 open or running | phase 2since Jun 7, 2018 | Jun 7, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Sep 10, 2004.
- May 14, 2007Phase 3 study in Stage IIIB or IV Non-Small Cell Lung CancerMerck · NCT00473889 · 253 enrolled
- May 24, 2007Phase 1 study in LeukemiaMerck · NCT00479232 · 71 enrolled
- Jun 14, 2007Phase 2 study in Myelodysplastic SyndromesMerck · NCT00486720 · 22 enrolled
- Feb 29, 2008Phase 1 study in Advanced Cancer RelapsedMerck · NCT00632931 · 25 enrolled
- Mar 17, 2008Phase 1 study in RecurrenceMerck · NCT00642954 · 31 enrolled
- Sep 8, 2008Phase 1 study in NeoplasmsMerck · NCT00750178 · 30 enrolled
- Oct 9, 2008Phase 1 study in LymphomaMerck · NCT00771472 · 10 enrolled
- Oct 14, 2008Phase 2 study in RecurrenceMerck · NCT00773838 · 143 enrolled
- Oct 14, 2008Phase 3 study in Multiple MyelomaMerck · NCT00773747 · 637 enrolled
- Mar 4, 2009Phase 1 study in Multiple MyelomaMerck · NCT00858234 · 9 enrolled
- Apr 2, 2009Phase 2 study in LymphomaMerck · NCT00875056 · 56 enrolled
- May 21, 2009Phase 2 study in Advanced CancerMerck · NCT00907738 · 27 enrolled
- Jun 7, 2018Jubilant DraxImage's first study: phase 2 study in NeuroblastomaNew to Jubilant DraxImageJubilant DraxImage · NCT03561259 · 60 enrolled · United States
- Aug 14, 2025Unravel Biosciences's first studies: 2 phase 1 studiesNew to Unravel BiosciencesUnravel Biosciences · NCT07150026, NCT07150013
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Pitt-Hopkins syndromeUnravel Biosciences · NCT07150026
- Dec 31, 2026Primary completion: phase 1 study in Rett SyndromeUnravel Biosciences · NCT07150013
TargetBeta
“Histone deacetylase 1 inhibitor; Histone deacetylase 3 inhibitor; Histone deacetylase 6 inhibitor; Histone deacetylase 2 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| givinostatrule | Italfarmaco | phase 3 | 23 |
| givinostat hydrochloriderule | Italfarmaco | phase 2 | 1 |
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07150026Pitt-Hopkins syndrome · Colombia | 1 | Recruiting | Unravel Biosciences | Dec 31, 2026 | 5 |
| NCT07150013Rett Syndrome · Colombia | 1 | Recruiting | Unravel Biosciences | Dec 31, 2026 | 15 |
| NCT03561259Neuroblastoma · United States | 2 | UNKNOWN | Jubilant DraxImage | Dec 1, 2023 | 60 |
| NCT00907738Advanced Cancer | 2 | Completed | Merck | Jun 2010 | 27 |
| NCT00875056Lymphoma | 2 | Completed | Merck | Sep 6, 2011 | 56 |
| NCT00858234Multiple Myeloma | 1 | Completed | Merck | Jun 11, 2010 | 9 |
| NCT00773838Recurrence | 2 | Completed | Merck | May 16, 2011 | 143 |
| NCT00773747Multiple Myeloma | 3 | Completed | Merck | Sep 8, 2011 | 637 |
| NCT00771472Lymphoma | 1 | Completed | Merck | Jul 2011 | 10 |
| NCT00750178Neoplasms | 1 | Completed | Merck | Aug 1, 2005 | 30 |
| NCT00642954Recurrence | 1 | Completed | Merck | Sep 3, 2012 | 31 |
| NCT00632931Advanced Cancer Relapsed | 1 | Completed | Merck | May 2008 | 25 |
| NCT00486720Myelodysplastic Syndromes | 2 | Terminated | Merck | Jul 2009 | 22 |
| NCT00479232Leukemia | 1 | Completed | Merck | Apr 2010 | 71 |
| NCT00473889Stage IIIB or IV Non-Small Cell Lung Cancer | 3 | Terminated | Merck | Dec 2008 | 253 |
| NCT00424775Neoplasms | 1 | Terminated | Merck | Mar 2007 | 3 |
| NCT00423449Carcinoma, Non-Small-Cell Lung | 1 | Completed | Merck | Apr 2010 | 61 |
| NCT00373490Neoplasms | 1 | Completed | Merck | Oct 2007 | 16 |
| NCT00251589Carcinoma, Non-Small-Cell Lung | 2 | Terminated | Merck | Oct 2007 | 23 |
| NCT00128102Mesothelioma | 3 | Completed | Merck | Jul 15, 2011 | 661 |
| NCT00127140Lymphoma | 1 | Completed | Merck | Apr 2012 | 10 |
| NCT00127127Neoplasms | 1 | Completed | Merck | Aug 21, 2009 | 18 |
| NCT00127101Lymphoma | 1 | Terminated | Merck | Oct 2008 | 23 |
| NCT00126451Breast Neoplasms | 2 | Terminated | Merck | Oct 11, 2005 | 16 |
| NCT00111813Multiple Myeloma | 1 | Completed | Merck | Dec 2009 | 34 |
| NCT00109109Multiple Myeloma | 1 | Terminated | Merck | Feb 14, 2006 | 60 |
| NCT00106626Carcinoma, Non-Small-Cell Lung | 1 | Completed | Merck | Dec 2007 | 52 |
| NCT00097929Lymphoma, B-Cell | 2 | Completed | Merck | Jul 31, 2006 | 18 |
| NCT00091559Lymphoma, T-Cell, Cutaneous | 2 | Completed | Merck | Nov 23, 2005 | 74 |
How it is read
Names in the registry
- “Vorinostat”, 12 entries
- “vorinostat”, 12 entries
- “Vorinostat (SAHA)”, 2 entries
- “MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months”, 2 entries
- “131-MIBG + Vorinostat”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 6 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Lymphoma, 4 studies
- Neoplasms, 3 studies
- Rett Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.